Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision ...

The kidney disease approval marks Apellis' third approval in four years. (Getty Images/Rasi Bhadramani) Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease ...

This study found that the recent change to remove race from the calculation of estimated glomerular filtration rate (eGFR) may incorrectly label potential donors who are Black as having chronic kidney ...

The FDA linked 12 severe kidney complications to alli between 2007 and 2023, resulting in 8 hospitalizations and 5 patients requiring dialysis. The Food and Drug Administration (FDA) has updated the ...

Eli Lilly LLY announced that the FDA has expanded the label of its diabetes drug, Jardiance (empagliflozin), to chronic kidney disease (“CKD”). Jardiance is now approved in the United States to reduce ...

HELSINKI, Dec 12 (Reuters) - The European Medicines Agency (EMA) will allow Novo Nordisk (NOVOb.CO), opens new tab to add risk reduction for events related to kidney disease to the label of its ...

GLP-1 drugs are being studied in a growing number of indications, and Novo Nordisk can now claim to have the first medication in this class approved for chronic kidney disease. The FDA has expanded ...

Sept 1 (Reuters) - U.S. health regulators on Thursday approved a label update to Novartis AG's osteoporosis drug Reclast to warn about the risk of kidney failure associated with the use of the drug.

Novo Nordisk drug Ozempic, already a blockbuster seller in type 2 diabetes, now has clinical trial results showing it reduced the risk of kidney disease complications by 24%. The company is planning U ...

Tarpeyo was first approved in December 2021 under accelerated approval based on the surrogate marker of proteinuria. Calliditas' Tarpeyo will continue to be priced at $15,123 per month and could ...